Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
Yi‐Long Wu(Guangdong Academy of Medical Sciences), Ying Cheng(Jilin Province Tumor Hospital), Jianying Zhou(First Affiliated Hospital Zhejiang University), Shun Lü(Shanghai Chest Hospital), Yiping Zhang(Zhejiang Cancer Hospital), Jun Zhao(Peking University), Dong‐Wan Kim(Seoul National University Hospital), Ross A. Soo(National University Cancer Institute, Singapore), Sang‐We Kim(Asan Medical Center), Hongming Pan(Sir Run Run Shaw Hospital), Yuh‐Min Chen(Taipei Veterans General Hospital), Chih‐Feng Chian(Tri-Service General Hospital), Xiaoqing Liu(Academy of Military Medical Sciences), Daniel S.W. Tan(National Cancer Centre Singapore), Rolf Bruns(Merck (Germany)), Josef Straub(Merck (Germany)), Andreas Johne(Merck (Germany)), J. Scheele(Merck (Germany)), Keunchil Park(Samsung Medical Center), James Chih‐Hsin Yang(National Taiwan University Hospital), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Xiaoqing Liu(Academy of Military Medical Sciences), Zhe Liu(Academy of Military Medical Sciences), Shun Lu(Shanghai Chest Hospital), Xi Chen(Taipei Veterans General Hospital), Hongming Pan(Sir Run Run Shaw Hospital), Mengzhao Wang, YU Shi-ying(Taipei Veterans General Hospital), Helong Zhang(Zhejiang Cancer Hospital), Yiping Zhang(Zhejiang Cancer Hospital), Jian Fang(First Affiliated Hospital Zhejiang University), Wei Li(Academy of Military Medical Sciences), Jianying Zhou(First Affiliated Hospital Zhejiang University), Jun Zhao(Peking University), Ying Cheng(Jilin Province Tumor Hospital), Chih-Hsin Yang(National Taiwan University Hospital), Gee‐Chen Chang, Yuh‐Min Chen(Taipei Veterans General Hospital), Te‐Chun Hsia, Chih‐Feng Chian(Tri-Service General Hospital), Cheng-Ta Yang(National Taiwan University Hospital), Chin‐Chou Wang, Sang‐We Kim(Asan Medical Center), Keunchil Park(Samsung Medical Center), Dong‐Wan Kim(Seoul National University Hospital), Byoung Chul Cho, Ki Hyeong Lee, Young‐Chul Kim(Asan Medical Center), Ho Jung An, In Sook Woo, Y. Choi, Sang Won Shin, Jong Seok Lee, Joo-Hang Kim(Asan Medical Center), Seung Soo Yoo, Terufumi Kato, Naofumi Shinagawa, Ross A. Soo(National University Cancer Institute, Singapore), Shao Weng Daniel Tan(National Cancer Centre Singapore), Lynette Si-Mien Ngo, Kananathan Ratnavelu, Azura Rozila Ahmad, Chong Kin Liam, Filippo de Marinis, Pierfrancesco Tassone, Amelia Insa Molla, Antonio Calles, Martín Emilio Lázaro Quintela, Enriqueta Felip Font, Anne‐Marie C. Dingemans, Lynne A. Bui
Cited by 258
Abstract
Related Papers
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al.|New England Journal of Medicine|2017|5.2k
<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean, Cameron Brennan, Jin‐Yuan Shih et al.|Proceedings of the National Academy of Sciences|2007|1.6k